Ajay Bansal
Director of Finance/CFO chez UROVANT SCIENCES LTD.
Profil
Ajay Bansal currently works at Urovant Sciences Ltd., as Chief Financial Officer & SVP-Business Development from 2019.
Mr. Bansal also formerly worked at Capital One Financial Corp., as Director-Operations Analysis from 2002 to 2003, Nektar Therapeutics, as Chief Financial Officer from 2003 to 2006, Lexicon Pharmaceuticals, Inc., as CFO & Executive VP-Business Development in 2010, Tercica, Inc., as CFO & Executive VP-Business Development from 2007 to 2008, Onconova Therapeutics, Inc., as Chief Financial Officer & Secretary from 2014 to 2016, ViewRay Technologies, Inc., as Chief Financial & Accounting Officer, Complete Genomics, Inc., as Chief Financial Officer from 2012 to 2013, ViewRay, Inc., as Chief Financial & Accounting Officer from 2016 to 2019, McKinsey & Co., Inc., as Engagement Manager from 1988 to 1991, Mehta Partners LLC, as Partner from 1998 to 2002, ZS Associates, Inc., as Consultant from 1985 to 1987, and Novartis Pharmaceuticals Corp., as Principal.
Mr. Bansal received his graduate degree in 1985 and Masters Business Admin degree in 1985 from Northwestern University and undergraduate degree in 1984 from Indian Institute of Technology New Delhi.
Postes actifs de Ajay Bansal
| Sociétés | Poste | Début |
|---|---|---|
| UROVANT SCIENCES LTD. | Director of Finance/CFO | 28/10/2019 |
Anciens postes connus de Ajay Bansal
| Sociétés | Poste | Fin |
|---|---|---|
| VIEWRAY, INC. | Director of Finance/CFO | 30/09/2019 |
| TRAWS PHARMA, INC. | Director of Finance/CFO | 12/02/2016 |
| COMPLETE GENOMICS, INC. | Director of Finance/CFO | 01/03/2013 |
| LEXICON PHARMACEUTICALS, INC. | Director of Finance/CFO | 08/01/2010 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Director of Finance/CFO | 01/10/2008 |
Formation de Ajay Bansal
| Northwestern University | Graduate Degree |
| Indian Institute of Technology New Delhi | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| CAPITAL ONE FINANCIAL CORPORATION | Finance |
| NEKTAR THERAPEUTICS | Health Technology |
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| TRAWS PHARMA, INC. | Health Technology |
| VIEWRAY, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Viewray Technologies, Inc.
 Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | Commercial Services |
Complete Genomics, Inc.
 Complete Genomics, Inc. BiotechnologyHealth Technology Complete Genomics, Inc. develops and markets DNA sequencing technology. It provides complete genomics analysis platform, which combines its proprietary human genome sequencing technology with the company's advanced informatics and data management software. The firm offers innovative, end-to-end, outsourced service model to the customers with data. The company was founded by Clifford A. Reid, Radoje T. Drmanac, David Smith and Robert John Curson in 2006 and is headquartered in San Jose, CA. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Mehta Partners LLC
 Mehta Partners LLC Investment ManagersFinance Founded in 1980, Mehta Partners LLC is a research firm located in New York City. The universe Mehta monitors includes biopharmaceutical companies in the U.S., Europe, Japan and emerging markets including Brazil, China, Eastern Europe and India. They cover 400 companies that are classified by geography and maturity. | Finance |
ZS Associates, Inc.
 ZS Associates, Inc. Miscellaneous Commercial ServicesCommercial Services ZS Associates, Inc. engages in the sales and marketing consulting, outsourcing, technology and software services. Its services include market segmentation, targeting, mergers, integration, forecasting and design. The company was founded by Prabhakant K. Sinha and Andy Zoltners in 1983 and is headquartered in Evanston, IL. | Commercial Services |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
